Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: Where do we stand?

Critical Reviews in Oncology/Hematology

Volumn 62, Issue 1, 2007, Pages 1-8

  Biganzoli, Laura ^a   Claudino, Wederson M ^a   Pestrin, Marta ^a   Pozzessere, Daniele ^a   Di Leo, Angelo ^a  

^a HOSPITAL OF PRATO   (Italy)

Author keywords

Adjuvant therapy; Breast cancer; Chemotherapy; Estrogen receptor; Her 2; Molecular biology; Tamoxifen

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROURACIL; NAVELBINE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CELL STRUCTURE; CLINICAL TRIAL; DECISION MAKING; GENE EXPRESSION; HUMAN; MOLECULAR DYNAMICS; PHYSICIAN; REVIEW;

EID: 33847261062     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.10.004     Document Type: Review

References (43)

1. Perez E.A., Pusztai L., and Van de Vijver M. Improving patient care through molecular diagnostics. Semin Oncol 31 (2004) 14-20
2. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 (2001) 10869-10874
3. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100 (2003) 10393-10398
4. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 16 (2005) 5678-5685
5. International Breast Cancer Study Group. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive breast cancer? First results of International Breast Cancer Study Group trial 11-93. Breast 10 Suppl. 3 (2001) 130-138
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet 365 (2005) 1687-1717
7. Pritchard K.I., Paterson A.H.G., Fine S., et al. Randomized trial of cyclophosphamide, methotrexate and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15 (1997) 2302-2311
8. Fisher B., Dignam J., Wolmark N., et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89 (1997) 1673-1682
9. Fisher B., Jeong J.H., Bryant J., et al. Findings from two decades of National Surgical Adjuvant Breast and Bowel Project clinical trials involving breast cancer patients with negative axillary nodes. Lancet 364 (2004) 858-868
10. International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 94 (2002) 1054-1065
11. International Breast Cancer Study Group (IBCSG). Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol 16 5 (2005) 716-725
12. Albain K., Barlow W., O'Malley F., et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on pahse III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat 88 (2004) S1 [Abstract 37]
13. National Institutes of Health Consensus Development Panel: Adjuvant Therapy for Breast Cancer. J Natl Cancer Inst 2001;93:979-89.
14. Goldhirsch A., Glick J.H., Gelber R.D., et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 meeting highlights: international consensus panel on the treatment of primary breast cancer. Ann Onc 16 (2005) 1569-1583
15. Lippman M.E., Allegra J.C., Thompson E.B., et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. New Engl J Med 298 (1978) 1223-1228
16. Harbeck N, Bohlmann I, Ross JS. Multicenter study validates PITX2 DNA methylation for risk prediction in tamoxifen-treated, node-negative breast cancer using paraffin-embedded tumor tissue. Proc Am Soc Clin Oncol 2005 [abstract 505].
17. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 27 (2004) 2817-2826
18. Paik S., Shak S., Tang G., et al. Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. Breast Cancer Res Treat 83 (2004) A24
19. Bergh J., Torbjorn N., Sigrid S., et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1 (1995) 1029-1034
20. Sjogren S., Inganas M., Norberg T., et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88 (1996) 173-182
21. Sjöström J., Blomqvist C., Heikkilä P., et al. Predictive Value of p53, mdm-2, p21, and mib-1 for Chemotherapy Response in Advanced Breast Cancer. Clin Cancer Res 6 (2000) 3103-3110
22. Lowe S.W., Ruley H.E., Jacks T., and Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 6 (1993) 957-967
23. Levine M.N., Bramwell V.H., Pritchard K.I., et al., National Cancer Institute of Canada Clinical Trials Group. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16 (1998) 2651-2658
24. Poole C.J., Earl H.M., Dunn J.A., et al. NEAT (National Epirubicin Adjuvant Trial), and SCTBG BR9601 (Scottish Cancer Trials Breast Group) Phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Proc Am Soc Clin Oncol 22 4 (2003) [abstract 13]
25. O'Connor P.M., Jackman J., Bae I., et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57 (1997) 4285-4300
26. Brown J.M., and Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59 (1999) 1391-1399
27. Bast R.C., Ravdin P., Hayes D.F., et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001) 1865-1878
28. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344 (2001) 783-792
29. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 53 16 (2005) 1673-1684
30. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 53 16 (2005) 1659-1672
31. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 8 (2006) 809-820
32. Robert N., Leyland-Jones B., Asmar L., et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 76 (2002) S37 [abstract 35]
33. ®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94 (2005) S5 [abstract 1]
34. Isaacs R.J., Davies S.L., Wells N.J., et al. Topoisomerases II alpha and beta as therapy targets in breast cancer. Anticancer drugs 6 2 (1995) 195-211
35. Jarvinen T.A.H., Tanner M., Barlund M., et al. Characterization of topoisomerase IIa gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26 (1999) 142-150
36. Jarvinen T.A.H., Tanner M., Rantanen V., et al. Amplification and deletion of topoisomerase IIa associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156 (2000) 839-847
37. Isola J., Tanner M., Holli K., et al. Amplification of topoisomerase IIa is a strong predictor of response to epirubicin-based chemotherapy in HER-2/neu positive metastatic breast cancer. Breast Cancer Res Treat 68 (2000) 31 [abstract 21]
38. Di Leo A., Gancberg D., Larsimont D., et al. HER-2 amplification and topoisomerase IIa gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with CMF. Clin Cancer Res 8 (2002) 1107-1116
39. Knoop A., Knudsen H., Balslev E., et al. Topoisomerase II alpha (TOP2A) alterations as a predictive marker for epirubicin sensitivity in 805 high-risk breast cancer patients. A randomised DBCG trial (DBCG89D). Eur J Cancer 1 (2003) S202 [abstract 674]
40. Pusztai L., Ayers M., Simmans F.W., et al. Emerging science: prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. J Clin Oncol (2003) 237s [abstract 1]
41. Chang J.C., Wooten E.C., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. The Lancet 362 (2003) 362-369
42. Hannemann J., Oosterkamp H.M., Bosch C.A.J., et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 23 (2005) 3331-3342
43. Rouzier R., Rajan R., Wagner P., et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102 (2005) 8315-8320